Clinical trial · Observational
Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy
NCT07473518CI-TRIAL-00105591recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to define the optimal surveillance strategy for children exposed to radiotherapy by assessing the incidence, risk factors, and timing of thyroid nodules and differentiated thyroid cancer. It also investigates the genetic features of thyroid tumors in this population to identify predictive biomarkers of onset, malignancy, and aggressiveness. Ultimately, the goal is to support more personalized management, including tailored surgery and targeted therapies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
| Thyroid Carcinoma | Thyroid Gland Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- To calculate the incidence of thyroid nodules and/or thyroid cancer in patients who were exposed and not exposed to radiotherapy
- timeFrame
- At 4 years after radiotherapy for the radiotherapy-exposed group; At the time of ultrasound for the non-radiotherapy group
- description
- Presence of thyroid nodules and/or thyroid cancer (yes/no)
- measure
- "To identify risk factors for the development of thyroid nodules and/or thyroid cancer in patients who underwent radiotherapy during childhood
- timeFrame
- At 4 years after radiotherapy
- description
- Presence of thyroid nodules and/or thyroid cancer (yes/no)
Secondary outcomes (1)
- measure
- To identify genetic biomarkers predictive of thyroid cancer development in the pediatric population, both exposed and not exposed to radiotherapy
- timeFrame
- At 4 years after radiotherapy for the radiotherapy-exposed group; At the time of ultrasound for the non-radiotherapy group
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
- Maximum age
- 43 Years
Show eligibility criteria text
INCLUSION CRITERIA For the group of oncologic patients who underwent radiotherapy: * Radiotherapy for an oncologic condition performed between January 1, 1999, and December 31, 2018; * Age at the time of radiotherapy \< 18 years; * Follow-up of at least 4 years conducted at the Endocrine-Metabolic Diseases Program, Pediatric Unit, IRCCS AOU Bologna; * Obtained informed consent For the group of subjects not exposed to radiotherapy and without specific risk factors for DTC: * No history of exposure to ionizing radiation; * No specific risk factors for DTC (autoimmune thyroiditis, familial forms, genetic syndromes); * Thyroid ultrasound performed between January 1, 1999, and December 31, 2018, at the Nuclear Medicine Unit of IRCCS AOU Bologna; * Age at the time of the thyroid ultrasound \< 18 years; * Obtained informed consent EXCLUSION CRITERIA: For the group of oncologic patients who underwent radiotherapy: * Patients transferred to another center before completing 4 years of follow-up after radiotherapy at the Pediatric Unit of IRCCS AOU Bologna, without having received a diagnosis of thyroid cancer. For the group of subjects not exposed to radiotherapy and without specific risk factors for DTC: * None.
References
Publications (0)
Data not yet available
No reference posted for this study.